DV
Dividend Vision

PHIO — Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp (PHIO)

Total return is -100.0% over the past 14.3 years, 731.4 points behind SPY at 631.4%. Its deepest 1-year drawdown was 65.5%.

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics, including PH-762 and PH-894, compounds designed to modulate immune response in cancer treatment through gene silencing technology. The company does not currently distribute dividends. Phio Pharmaceuticals appeals primarily to investors seeking exposure to early-stage biotech development with potential for significant long-term capital appreciation rather than current income.

PHIO key facts

Asset type
Stock
Asset class
Equity
Inception date
05/10/2012
Last close
$1.09
Market cap
$13,127,494
Average volume
94600.0
Payment date
01/15/2020
Beta
0.81
Payout ratio
0.0
Forward P/E
0.3064
EPS
$-1.44